Testing safety of KSHN001034 in healthy postmenopausal women
Treatments studied
This study tests how safe and tolerable a new drug, KSHN001034, is in healthy women who have gone through menopause. It involves multiple doses to see how your body processes the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy, postmenopausal women aged 45 to 60
- Body mass index between 18 and 30
- At least 12 months since your last period, or if under 50, a blood test confirming menopause
- Able to give blood samples and follow study procedures
- No major health issues like heart, liver, or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety of a new medicine called IMC-003. It is for healthy women who have gone through menopause. You may be able to join if you are between 45 and 75 years old and meet certain health criteria.
This trial tests different doses of a new study drug in healthy people to see how safe it is and how the body handles it. Participation involves taking the drug and having regular check-ups.
This trial tests a single injection of BL0175 in postmenopausal women to see how the body processes it and whether it is safe. It may help if you are looking for new treatment options for certain conditions in postmenopausal women.
This is an early-stage safety test of a new investigational drug called HSK56630 in healthy volunteers with no major medical conditions. Researchers will monitor how your body tolerates the drug and what side effects might occur.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
Hear when a new Healthy Postmenopausal Women trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.